Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 34 for “"TKIs"”.
-
Συστηματική ανασκόπηση: αποτελεσματικότητα και ασφάλεια των αναστολέων κινάσης τυροσίνης στο χολαγγειοκαρκίνωμα / Efficacy and safety of tyrosine kinase inhibitors in cholangiocarcinoma: a comprehensive systematic review
… στάδια. Οι αναστολείς τυροσινικής κινάσης (TKIs) έχουν αναδυθεί ως στοχευμένη θεραπευτική επιλογή με αυξανόμενο ενδιαφέρον στην ογκολογία, ιδίως σε μοριακά επιλεγμένους ασθενείς. Σκοπός της παρούσας συστηματικής ανασκόπησης ήταν η αξιολόγηση της αποτελεσματικότητας και της ασφάλειας των TKIs …
-
Expression and function of drug transporters in primitive CML cells
… that are relatively insensitive to IM and other TKIs and which may be responsible for the molecular persistence of this disease. This population may be insensitive because TKIs do not reach therapeutic concentrations within the cell. Such resistance to classical chemotherapeutic drugs, the …
-
Role of Membrane Transporters in Drug Delivery, Drug Disposition And Drug-Drug Interactions
… the disposition of tyrosine kinase inhibitors (TKIs). Since selected TKIs are the substrates and/or inhibitors of OATP-1B1 and -1B3 expressed in hepatic tissue, these compounds can be regarded as molecular targets for transporter mediated drug-drug interactions (DDIs). Any alteration in the …
-
Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos.
… tratamiento con inhibidores de tirosin quinasa (TKIs) en pacientes oncológicos, al igual que el de cualquier otro tratamiento, es lograr la máxima efectividad terapéutica con la mínima toxicidad iatrogénica. Sin embargo, las pautas posológicas necesarias para lograr los efectos terapéuticos …
-
Βιβλιογραφική ανασκόπηση χορήγησης οσιμερτινίμπης σε ασθενείς με μη μικροκυτταρικό καρκίνο πνεύμονα και θετικές μοριακές μεταλλάξεις EGFR/ Literature review of osimertinib administration in patients with non-small cell lung cancer and positive EGFR molecular mutations
… της οσιμερτινίμπης έναντι παλαιότερων EGFR-TKIs ως προς PFS και OS, καθώς και καλύτερο έλεγχο εγκεφαλικών μεταστάσεων. Η προσθήκη πλατίνας–πεμετρεξέδης στην πρώτη γραμμή παρατείνει περαιτέρω την PFS, με τίμημα αυξημένη τοξικότητα και μεγαλύτερη ανάγκη υποστηρικτικής φροντίδας. Στην …
-
Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines
… the ability of three tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib and lapatinib, to circumvent resistance to docetaxel, and other chemotherapeutic agents, arising from P-gp over-expression. A HPLC – based method was initially employed to quantify docetaxel levels in cells. The very high …
-
Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma
… soon after starting treatment. Hence, whilst ALK TKIs hold much promise for the treatment of ALCL, there remain clinical issues that need to be addressed. One approach would be the introduction of a second targeted drug that has a different mechanism of action to be used in combination with ALK …
-
Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance
… receptor (EGFR) tyrosine kinase inhibitors (TKIs) or monoclonal antibodies targeting vascular endothelial growth factor (VEGF/R), can effectively inhibit upregulated signaling pathways driving tumorigenesis in NSCLC and many other cancers. Unfortunately, however, resistance to such targeted …
-
The analysis of Bcr-Abl—Nox signalling in chronic myeloid leukaemia
… of Bcr-Abl-specific tyrosine kinase inhibitors (TKIs) there has been a substantial improvement in the clinical treatment of CML. Unfortunately, residual disease and the development of TKI resistance has become an ever growing concern, resulting in the need for a greater understanding of the …
-
The Investigation of Targets for Therapy in Brain Tumours
… A number of tyrosine kinase inhibitors (TKIs) have been developed and tested in clinical trials with mixed results. In collaboration with Beaumont hospital 31 glioma cell cultures were established to identify molecular markers indicative of responsiveness to EGFR and PDGFR blockade. Each …
-
Novel Mechanisms of Kinase Independent Pro-Survival Functions of EGFR in Cancer
… sensitized prostate cancer cells to EGFR TKIs. However, the role of SGLT1 in EGFR kinase inhibited conditions were not known. In the second approach of this dissertation, we have demonstrated that SGLT1 undergoes oligomerization and upon treatment with EGFR TKIs, enhances its …
-
An in vivo RNAi therapy screen identifies novel mediators of leukemia-microenvironment interaction
… despite the use of tyrosine kinase inhibitors (TKIs) as additional therapeutics that directly inhibit BCR-ABLI, more than half of BCR-ABLI+ BCP-ALL patients will experience a relapse. We have adapted an in vivo RNAi screening approach to perform novel longitudinal studies both in mice and in …
-
GENERATION OF SYNTHETIC ANTIBODIES AS POTENTIAL THERAPEUTICS TO BLOCK IL3–MEDIATED INNATE IMATINIB RESISTANCE IN CHRONIC MEYLOID LEUKEMIA
… (Ross et al., 2013) implicating the inability of TKIs in eradication of leukemic stem cells (LSCs). Accumulating evidence demonstrates that bone marrow stromal cell secreting factors, such as Interleukin 3 (IL3) hinder TKI activity and support CML–LSCs to survive the therapy with innate drug …
-
Response to treatment with chemical and biological inhibitors of c-met mutated form
… through the use of tyrosine kinase inhibitors (TKIs) have recently been started. The aim of project was: (i) to evaluate if METPRC mutants are sensitive to PHA-665752 (a small kinase inhibitor of MET), (ii) if some mutants are insensitive to the inhibitor, to investigate the mechanisms …
-
Mechanism of resistance to tyrosine kinase inhibitors in philadelphia-positive acute lymphblastic leukaemia (all): from genetic alterations to impaired RNA editing
… the response to tyrosine kinase inhibitors (TKIs) and contributes to resistance, an imatinib-sensitive Ik6-negative Ph+ ALL cell line (SUP-B15) was transfected with the complete Ik6 DNA coding sequence. The expression of Ik6 strongly increased proliferation and inhibited apoptosis in TKI …
-
EFFECT OF COMBINATION OF THE MAMMALIAN LIGNAN, ENTEROLACTONE, WITH TYROSINE KINASE INHIBITORS ON MARKERS OF HEPATIC FIBROSIS
… (ENL), and selected tyrosine kinase inhibitors (TKIs) and to explore whether these effects involve peroxisome proliferator-activated receptor gamma (PPARγ), oxidative stress, and/or endoplasmic reticulum (ER) stress, known pathways of lignan and TKI action. A standard PPARγ competitive binding …
-
TARGETING THE DNA DAMAGE RESPONSE PATHWAY FOR THE TREATMENT OF AGGRESSIVE THYROID CANCERS, IN VITRO STUDIES
… line treatments and tyrosine kinase inhibitors (TKIs). Though, part of them as well as Poorly Differentiated and Anaplastic TC are particularly aggressive and refractory both to first-line and TKI treatments, such as Lenvatinib (LENV). In other aggressive tumours (NSCLC, HCC, CML), TKI resistance …
-
Pharmacological modulation and manipulation of cancer drug resistance
… therapies, including tyrosine kinase inhibitors (TKIs, such as lapatinib), are the latest significant development in the treatment of cancer. Lapatinib sensitised HER2-expressing cell lines to chemotherapeutic agents in the presence or absence of EGFR expression. This agent was also found to be a …
-
The Role of Protocadherin 7 in Lung Adenocarcinoma
… mutant cell lines to tyrosine kinase inhibitors (TKIs), the current method of treatment for EGFR mutant lung cancers. Furthermore, loss of PCDH7 in EGFR mutant xenografts and genetically engineered mice reduces overall tumor burden. Overall, these findings reveal a new mechanism through which …
-
The Role of Protocadherin 7 in Lung Adenocarcinoma
… mutant cell lines to tyrosine kinase inhibitors (TKIs), the current method of treatment for EGFR mutant lung cancers. Furthermore, loss of PCDH7 in EGFR mutant xenografts and genetically engineered mice reduces overall tumor burden. Overall, these findings reveal a new mechanism through which …
Page 1 of 2